Ahead of the pivotal data readout of MyoKardia’s lead drug, mavacamten, in patients with obstructive hypertrophic cardiomyopathy (HCM), investors took issue with the drug’s safety profile in a separate Phase II non-obstructive HCM study.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2023,